why choose us

First received: November 11, 2024

Clinical Trial: Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Crimean Congo Hemorrhagic Fever

Study Type: INTERVENTIONAL


Official Title: A Phase I Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever

Brief Summary: This First-in-human dose-escalation vaccine phase I study aims to evaluate safety and reactogenicity of the investigational vaccine N-pVAX1, against Crimean Congo Hemorrhagic Fever, delivered by in vivo EP given as three im doses at weeks 0, 4 and 12.

Read more